Kodiak Sciences Inc. (KOD)

Market Cap	117.68M
Revenue (ttm)	n/a
Net Income (ttm)	-232.75M
Shares Out	52.53M
EPS (ttm)	-4.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,714
Open	2.350
Previous Close	2.370
Day's Range	2.230 - 2.350
52-Week Range	1.370 - 7.840
Beta	2.43
Analysts	Sell
Price Target	3.25 (+45.09%)
Earnings Date	Aug 12, 2024

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative dia...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: KOD

Analyst Forecast

According to 7 analysts, the average rating for KOD stock is "Sell." The 12-month stock price forecast is $3.25, which is an increase of 45.09% from the latest price.

Price Target

$3.25

(45.09% upside)

Analyst Consensus: Sell